Alphaket Capital

Alphaket Capital

Investment Thesis

Alphaket Capital is a quantum-only venture firm run by Mike Keymer, who spent more than 20 years at the intersection of advanced technology and market adoption and most recently led commercial strategy, partnerships and application deployment at a publicly traded quantum hardware company. The firm's stated premise is "closing the quantum adoption gap": technical breakthroughs must be matched with product discipline, market clarity matters as much as scientific novelty, and go-to-market execution determines outcomes. It says it backs founders building real quantum technology businesses, not research projects.

The Decile Access fund page sharpens this into two bets. First, the middle of the quantum stack: components that let any winning platform scale, such as transducers, interconnects, repeaters and memory, which Keymer argues become foundational across modalities and give LPs exposure to the quantum supply chain rather than a single architecture bet. His September 2025 essay argues the quantum network stack, which lets processors be networked into modular, heterogeneous systems, is the tipping point for mass adoption. Second, targeted quantum sensing for defense, healthcare, energy and life sciences, where the physics already does something classical hardware cannot and the path to revenue is near term.

Stage Focus

Pre-seed and seed only. Alphaket Fund I is described as a first-check fund; it states plainly that at $5M it cannot lead later rounds and depends on larger funds for follow-on capital.

Check Size

The website says check sizes up to $250,000. The Decile Access page says first checks of around $100,000. Portfolio construction is concentrated, with a long fund horizon.

Lead Tendency

Not stated. As a first-check fund with a tiny vehicle it likely takes small positions alongside others, but no public deal evidence exists, so this is recorded as unknown.

Recent Activity and Fund Status

Alphaket Fund I is a $5M US-focused vehicle with select investments in US-allied countries, 2% management fee, 20% carry, $100K minimum LP commitment for US accredited investors, offered under Rule 506(c). As of the Decile Access listing, 9 of 30 LP spots were available, so the fund is still raising. Keymer appeared on the Top Decile Podcast (August 2026), is listed as a speaker at the Optica 2026 Quantum Industry Summit, and is attending the Q2B Chicago Quantum Summit. No portfolio investments have been publicly announced, and the website has no portfolio page. This profile therefore carries no portfolio companies.

Portfolio Highlights

None public. Researchers should revisit once the fund announces its first checks.

Team

Mike Keymer is Founding Partner (also styled Founder and Investment Lead, and General Partner on third-party sites). He has founded and grown ventures across defense, financial services and life sciences, and brings a network of quantum hardware operators, enterprise quantum customers, government and defense buyers, and life sciences operators. LinkedIn: linkedin.com/in/mkeymer. The firm lists 2-10 employees on LinkedIn, but only Keymer is named.

Decision Process

Effectively a solo GP. Keymer makes the investment decisions and says he works alongside founders to help them land their first real enterprise and government contracts, which he argues makes portfolio companies more financeable to later-stage investors.

Founder Preferences

Technical founders building commercially oriented quantum hardware, components and sensing products with a credible near-term path to revenue and a clear buyer. Third-party listings suggest a warm intro is preferred; the site also offers a pitch submission form via Decile Hub. The firm avoids concentrating in any single modality (superconducting, trapped ion, photonic, neutral atom) and prefers founders whose products serve heterogeneous downstream platforms.

Geographic Focus

United States first, with select investments in US-allied countries. Office: 4075 Wilson Blvd, 8th Floor, Arlington, Virginia.

Risks the Firm Names

Quantum's commercial timeline slipping by five to ten years, backing the wrong physics platform, and the small fund size limiting follow-on ability.